Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Cariprazine is an atypical antipsychotic prescribed to treat schizophrenia in adults. It works differently from many older antipsychotics: instead of simply blocking dopamine receptors in the brain, cariprazine acts as what's called a partial agonist at dopamine D2 and D3 receptors. This means it can dial down activity when dopamine signalling is too high, and dial it up slightly when dopamine levels are low. Cariprazine has a stronger preference for D3 receptors, which are concentrated in a brain region called the ventral striatum. Because of this selectivity, it may produce fewer movement-related side effects than some other antipsychotics, which tend to act more broadly on dopamine pathways involved in motor control. Cariprazine also interacts with serotonin 5-HT1A receptors, though less strongly than it does with dopamine receptors. Early studies in animals suggest cariprazine might support cognitive function, but further research is needed to confirm this in humans.
Cariprazine has an unusually long presence in the body. The parent drug has a half-life of two to four days, but its active breakdown products remain much longer—one to three weeks. This means the medication continues working for some time after the last dose, and it takes longer to reach stable levels in the bloodstream when treatment begins or doses change. The medication is broken down primarily by a liver enzyme called CYP3A4, and to a lesser extent by CYP2D6. Because of this, cariprazine cannot be taken alongside strong or moderate CYP3A4 inhibitors or inducers, as these can significantly alter how much of the drug stays in the body.
The most commonly reported side effects are akathisia—a feeling of restlessness or an urge to move—which occurs in around 19 per cent of people, and parkinsonism—stiffness, tremor, or slowed movement—affecting about 17.5 per cent. Sleep disturbances, anxiety, and sedation are also reported. Serious but less common risks include neuroleptic malignant syndrome, a rare life-threatening reaction involving fever, muscle rigidity, and confusion; tardive dyskinesia, which involves involuntary repetitive movements that may persist even after stopping the medication; and suicidal thoughts or behaviour. Rare cases of toxic hepatitis and Stevens-Johnson syndrome, a severe skin reaction, have also been documented. Cariprazine should not be used in anyone with a known allergy to the medication or any of its ingredients.
“REAGILA® is an atypical antipsychotic. It is an orally active and potent dopamine D3 /D2 receptor partial agonist with preferential binding to D3 receptors and partial agonist at serotonin 5-HT1A receptors.”
“The mean terminal half-life (1 to 3 days for cariprazine and DCAR and 13 to 19 days for DDCAR) is not predictive of time to reach steady state or plasma concentration decline after treatment discontinuation. For the management of patients treated with REAGILA®, the effective half-life is more relevant than the terminal half-life. The effective (functional) half-life is ~ 2 days for cariprazine and DCAR, 8 days for DDCAR and is ~1 week for total cariprazine.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Cariprazine is an atypical antipsychotic with a distinctive mechanism: it acts as a partial agonist at dopamine D₂ and D₃ receptors, with preferential affinity for D₃, and also demonstrates partial agonist activity at serotonin 5-HT₁A receptors. Unlike many antipsychotics that function as D₂ antagonists, cariprazine modulates dopaminergic tone bidirectionally—inhibiting overstimulated receptors and stimulating them when endogenous dopamine levels are low. Its preferential D₃ binding may reduce motor side effects, because D₃ receptors are concentrated in the ventral striatum rather than the dorsal striatum implicated in extrapyramidal symptoms. The TGA-approved indication is treatment of schizophrenia in adult patients.
The pharmacokinetic profile is complex. Cariprazine is metabolised by CYP3A4 and, to a lesser extent, CYP2D6, forming active metabolites DCAR and DDCAR. The terminal half-life is prolonged—1 to 3 days for the parent compound and DCAR, but 13 to 19 days for DDCAR—though the effective (functional) half-life is approximately 2 days for cariprazine and DCAR, 8 days for DDCAR, and roughly 1 week for total cariprazine. Concomitant use with strong or moderate CYP3A4 inhibitors or inducers is contraindicated. Common adverse effects include akathisia (19%), parkinsonism (17.5%), sleep disturbance, anxiety, and sedation. Serious adverse effects—neuroleptic malignant syndrome, tardive dyskinesia, suicidal behaviour, toxic hepatitis, and Stevens–Johnson syndrome—are documented. Cariprazine is contraindicated in patients with known hypersensitivity to the drug or its excipients.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“REAGILA® is metabolised by CYP3A4 and, to a lesser extent, by CYP2D6, to DCAR and HCAR. DCAR is further metabolised by CYP3A4 and to a lesser extent by CYP2D6 into DDCAR and HDCAR. DDCAR is further metabolised to HDDCAR by CYP3A4.”